Prostate-specific membrane antigen (PSMA) is an attractive target due to its pronounced overexpression in a variety of tumours, most notably in prostate cancer.
We describe a protein vector that selectively delivers synthetic dsRNA, polyinosinic/polycytidylic acid (polyIC), to prostate tumors by targeting prostate specific membrane antigen (PSMA), which is overexpressed on the surface of prostate cancer cells.The chimeric protein is built from the double stranded RNA (dsRNA) binding domain of PKR tethered to a single chain anti-PSMA antibody.
We have successfully completed a phase I and phase II clinical trials on immunotherapy of prostate cancer using naked DNA and adenoviral immunizations against the prostate-specific membrane antigen (PSMA) and phase I clinical trial on colorectal cancer using naked DNA immunization against the carcinoembryonic antigen (CEA).
Positron emission tomography (PET) for prostate-specific membrane antigen (PSMA) represents a promising method for prostate cancer diagnosis and staging.
The prostate-specific membrane antigen is a cell-surface glycoprotein that is highly and specifically expressed on prostate epithelial cells and strongly upregulated in prostate cancer at all stages.
A 66-year-old man with prostate cancer underwent F-fluorocholine PET/CT and thereafter Ga-labeled prostate-specific membrane antigen PET/CT to explore a rising prostate-specific antigen level.
The aim of this study was to assess the intensity of <sup>68</sup>Ga-PSMA-11 uptake in the primary tumour and metastases in patients with biopsy-proven PC prior to therapy, and to determine whether a correlation exists between the primary tumour-related <sup>68</sup>Ga-PSMA-11 accumulation and the Gleason score (GS) or prostate-specific antigen (PSA) level.
<b>Methods:</b> Six patients (aged 62-68 y; mean, 66 ± 2 y) with suspected prostate cancer recurrence after previous treatment were administered 2 MBq of <sup>18</sup>F-PSMA-11 per kilogram of body weight and then underwent low-dose PET/CT imaging at 0, 20, 50, 90, and 300 min after injection.
Prostate-specific membrane antigen (PSMA) is overexpressed in a majority of prostate cancer cells, which has led to the development of radiolabeled small-molecule inhibitors of PSMA for molecular imaging and targeted radioligand therapy.
To achieve a prostate cancer-specific delivery for in vivo testing, we conjugated the most potent saV2-9 RNA molecule with the prostate-specific membrane antigen (PSMA)-targeting aptamer A10-3.2.
To determine the patterns of progression after <sup>68</sup>Ga prostate-specific membrane antigen (PSMA)-ligand positron emission tomography (PET)/computed tomography (CT)-guided radiation therapy (RT) for recurrent oligometastatic prostate cancer (PCa).
<b>Conclusion:</b> In this pilot study, <sup>18</sup>F-PSMA-1007 PET/CT presented high potential for localization of recurrent disease in prostate cancer patients with BCR.
The introduction of <sup>18</sup>F-labeled prostate-specific membrane antigen (PSMA)-targeted PET/CT tracers, first <sup>18</sup>F-DCFPyL (2-(3-{1-carboxy-5-[(6-<sup>18</sup>F-fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid) and more recently <sup>18</sup>F-PSMA-1007 (((3<i>S,</i>10<i>S,</i>14<i>S</i>)-1-(4-(((<i>S</i>)-4-carboxy-2-((<i>S</i>)-4-carboxy-2-(6-<sup>18</sup>F-fluoronicotinamido)butanamido)butanamido)methyl)phenyl)-3-(naphthalen-2-ylmethyl)-1,4,12-trioxo-2,5,11,13-tetraazahexadecane-10,14,16-tricarboxylic acid)), have demonstrated promising results for the diagnostic workup of prostate cancer.
<b>Conclusion:</b> The radiofluorinated PSMA ligand showed promising characteristics in its preclinical evaluation, and the feasibility of prostate cancer imaging was demonstrated by small-animal PET studies.